Suven to participate in 11th clinical trials on Alzheimer’s disease in Spain
Suven Life Sciences is participating and presenting the baseline patient demographics and scales from the ongoing phase-2a proof-of-concept trial of SUVN-502 for moderate Alzheimer’s Disease at 11th clinical trials on Alzheimer’s disease (CTAD) during October 24-27, 2018 at Barcelona, Spain. SUVN-502 is a promising pure, 5-HT6 receptor antagonist in development for the treatment of moderate … Read more



